VRC 012 (07-I-0167)

VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) May 01, 2007
VRC-HIVADV038-00-VP,VRC-HIVADV027-00-VP Ad35 Env A; Ad5 Env A
VRC-HIVADV027-00-VP Viral Vector - Adeno
VRC-HIVADV038-00-VP Viral Vector - Adeno
USA 35